Posts

FDA Staff Signal Replimune RP1 Melanoma Trial Failure, Slashing Stock

on

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

on

Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

Daiichi Sankyo Postpones FY2026 Earnings Announcement to May 11, Shares Plunge 10%

on

Roche's Giredestrant Fails Primary Endpoint in Phase 3 Breast Cancer Trial

on

Grail's Galleri Cancer Test Misses Primary Endpoint in NHS Trial, Shares Plunge Despite Positive Trends

on

Cardiff Oncology Stock Craters Amid Executive Exits and Mixed Mid-Stage Data

on

Weight-loss drug stocks drop after Trump pledges major price cuts

on

Novo Nordisk's Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

on

Replimune's Shares Plunge After FDA Rejects Melanoma Drug Application

on

Novo Nordisk's CagriSema Weight Loss Drug Trial Results Disappoint Investors

on

Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial

on